We will inspire changes in structures and cultures to remove racism. We will advocate using our influence and understanding to speak up for racial equality and equity in the church and the city. We will Identify actions to bring healing.

We aim for truth, reconciliation and healing through open discussions across the city, that understands and acknowledges the hurts of the past and hopes for the future. We will bridge the knowledge gap, building a shared understanding of what it is like to be black, or of other ethnicity in Birmingham today, understanding the historical context and the damage to their psyche by sustained and systemic racism. We will build a culture of honour, openness and support within our churches, neighbourhoods and workplaces. We commit to relationship building with church and city leaders modelling strong supportive relationships across the city. We will listen to the voices of our black and all ethnic communities, across the generations and the different parts of our city. We will engage in conversations - creating the spaces for open, honest and frank dialogue. We repent – we have caused or ignored hurt and we pray for a deep healing in our city. We will pray: actively encouraging prayer as a group and within and across our churches and neighbourhoods over the issue of racial injustice and disunity. We commit to an honest and open look at ourselves and our churches and where we are in relation to the issue of racial injustice. We commit to challenge racism confidently across Birmingham and see it removed from the church and society. on behalf of AlphaMed Press.We the churches, Christian organisations and followers of Jesus acknowledge the issue of racial injustice and its systemic and institutional nature. © 2017 The Authors Stem Cells Translational Medicine published by Wiley Periodicals, Inc. MSCs Medicinal signaling cells Mesenchymal stem cells Regenerative medicine. Stem Cells Translational Medicine 2017 6:1445-1451. It is, indeed, the patient's own site-specific and tissue-specific resident stem cells that construct the new tissue as stimulated by the bioactive factors secreted by the exogenously supplied MSCs. I now urge that we change the name of MSCs to Medicinal Signaling Cells to more accurately reflect the fact that these cells home in on sites of injury or disease and secrete bioactive factors that are immunomodulatory and trophic (regenerative) meaning that these cells make therapeutic drugs in situ that are medicinal. Such a stem cell treatment will presumably cure the patient of their medically relevant difficulties ranging from osteoarthritic (bone-on-bone) knees to various neurological maladies including dementia. Unfortunately, the fact that MSCs are called 'stem cells' is being used to infer that patients will receive direct medical benefit, because they imagine that these cells will differentiate into regenerating tissue-producing cells.

Today, there are hundreds of clinics and hundreds of clinical trials using human MSCs with very few, if any, focusing on the in vitro multipotential capacities of these cells. The in vitro capacity to form bone, cartilage, fat, etc., became an assay for identifying this class of multipotent cells and around which several companies were formed in the 1990s to medically exploit the regenerative capabilities of MSCs. Mesenchymal stem cells (MSCs) were officially named more than 25 years ago to represent a class of cells from human and mammalian bone marrow and periosteum that could be isolated and expanded in culture while maintaining their in vitro capacity to be induced to form a variety of mesodermal phenotypes and tissues.

Time for change